

MATERIAL CHANGE REPORT**PURSUANT TO SECTION 7.1 OF NATIONAL INSTRUMENT 51-102****1. Name and Address of Company:**

Miraculins Inc. (the "Company")
6 – 1250 Waverley Street
Winnipeg, Manitoba R3T 6C6

2. Date of Material Change:

September 18, 2013

3. News Release:

The Company issued a press release regarding the material change on August 8, 2013, a copy of which is attached hereto.

4. Summary of Material Change:

WINNIPEG, Manitoba – August 8, 2013 - Miraculins Inc. (TSX-V:MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, is pleased to announce that it has engaged Network IR ("Network"), to develop and execute a comprehensive investor communications program to raise awareness of the Company within the North American and International investment communities.

5. Full Description Of Material Change:

See attached Schedule "A".

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102:

Not Applicable.

7. Omitted Information:

Not Applicable

8. Executive Officer:

Christopher Moreau, Chief Executive Officer
Tel: (204) 453-1408

DATED at Winnipeg, Manitoba this 2nd day of August, 2013.

MIRACULINS INC.

Per: "Christopher Moreau"
Chris Moreau President & CEO

SCHEDULE "A"

Miraculins Retains Network IR to Provide Investor Relations

Vancouver Firm to Enhance Market Communications of Miraculins Advances Including its Acquisition of the SCOUT DS[®] Non-Invasive Diabetes Testing Technology

WINNIPEG, Manitoba – August 8, 2013 - Miraculins Inc. (TSX-V:MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, is pleased to announce that it has engaged Network IR ("Network"), to develop and execute a comprehensive investor communications program to raise awareness of the Company within the North American and International investment communities.

"Investor communications is of paramount importance to a growing public company like Miraculins, and recent corporate advances warrant a greater exposure to a broader investment audience," said Christopher J. Moreau, President and Chief Executive Officer of Miraculins Inc. "Miraculins and Network will work to develop a heightened outreach program so that we can more effectively communicate our progress including advances with our PreVu[®] skin cholesterol testing technology and our new SCOUT DS[®] diabetes testing technology to current and prospective investors alike."

Network is a Vancouver-based full service investor relations company with experience in creating exposure for companies to industry stakeholders and investors. Network strives to represent companies that fall under the "best of breed" category for their specific focus area. Network's service will include consulting to Miraculins with respect to corporate development and finance, producing and distributing effective investor communications tools, and increasing investor awareness.

Under the terms of the services agreement, and subject to TSX-V approval, Network has been hired for an initial term of three months, renewable on a monthly basis thereafter on mutual agreement. Network will be paid a monthly fee of \$7,500.

About Network IR

Network IR is one of Canada's premier full service investor relations companies. Network IR provides its client companies with exposure, presence and access to the heart of the public markets. To date, the Network team have assisted in raising over \$100 Million in equity finance and have helped numerous client companies reach their development goals and significant market capitalization. For more information on Network IR, visit their corporate website at <http://www.networkir.com/>

About Miraculins Inc.

Miraculins is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. A significant number of promising diagnostic opportunities remain un-commercialized because of the sizable gap between the discovery stage, when research institutions are typically involved, and the commercialization stage, when the larger commercial enterprises become interested. Miraculins has direct experience in bridging this gap. The Company's PreVu[®] technology is a revolutionary new coronary artery disease risk assessment technology that measures cholesterol levels in a patient's skin non-invasively, painlessly and without the need for fasting. The Company's SCOUT

DS[®] system, is the first non-invasive diabetes screening system designed to provide a highly sensitive and convenient method for screening for pre-diabetes and type 2 diabetes based on the presence of diabetes-related biomarkers found in skin. Unlike current screening methods, a SCOUT DS[®] test requires no blood draw, no fasting, and no waiting for a lab result. The product has been used and validated in thousands of patients around the world. The Company's preeclampsia program is partnered with Alere Inc., one of the world's largest diagnostic companies. For more information visit www.miraculins.com.

For more information, please contact:

Christopher J. Moreau
President & CEO
Miraculins Inc.
Ph: 204-477-7599
Fax: 204-453-1596

info@miraculins.com
www.miraculins.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins' early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins' filings with Canadian securities regulatory authorities, as well as Miraculins' ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins' forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should

not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.

PreVu[®] and SCOUT DS[®] are registered trademarks of Miraculins Inc. All Rights Reserved. 2013.